METASTATIC NEUROENDOCRINE TUMOR
Clinical trials for METASTATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for METASTATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise against rare cancers
Disease control OngoingThis study tests whether adding the drug triapine to standard radioactive therapy (Lutathera) can better shrink or slow the growth of advanced neuroendocrine tumors that have spread. About 94 adults with these rare cancers will receive either the combo or standard treatment alone…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:47 UTC
-
New drug combo shows promise for rare gut tumors
Disease control OngoingThis early-phase trial tests a new combination of two drugs (triapine and lutetium Lu 177 dotatate) for people with advanced neuroendocrine tumors of the digestive system. The main goal is to find the safest dose and check for side effects. About 31 adults whose tumors have grown…
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:36 UTC
-
New drug shows promise in slowing carcinoid tumors
Disease control OngoingThis study tests a drug called pazopanib in 171 people with carcinoid tumors that are getting worse. The goal is to see if pazopanib can slow or stop tumor growth compared to a placebo. Participants take the drug daily and are monitored for how long their disease stays stable.
Matched conditions: METASTATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC